文献速递肝病

人类NAFLD基因组学:数据可重复性差与药物靶点表达患者间高变异性是药物失败主因

Genomics of human NAFLD: Lack of data reproducibility and high interpatient variability in drug target expression as major causes of drug failures.
PubMed 文献 · Hepatology · 2024-02-15

该研究分析418例NAFLD肝活检(含278例NASH),评估9项独立研究中差异表达基因的可重复性及18个药物靶点的患者间变异性。发现仅平均4%的差异基因在相同性别下共同调控,2%在相同NAS评分和纤维化分级下共同调控;除SCD外,多数药物靶点在超过80%患者中未受调控。数据可重复性差、患者间高变异性和缺乏疾病依赖性靶点调控可能是NASH药物临床试验失败的原因。

要点

  • NAFLD基因组数据跨研究可重复性差,仅少数差异基因被共同调控。
  • 药物靶点表达患者间变异性高,多数靶点在超过80%患者中未调控。
  • 性别影响基因调控,女性炎症反应基因诱导,男性细胞外基质受体交互上调。

核心结论

  • 数据可重复性差、患者间高变异性及缺乏疾病依赖性药物靶点调控可能是NASH药物临床试验失败的原因。

研究设计与样本

  • 研究纳入418例NAFLD肝活检(其中278例为NASH),并检索公共数据库的NAFLD活检基因组数据集,考虑患者人口学特征。
  • 数据分为测试集和验证集,评估差异表达基因的可重复性并进行基因富集分析,按疾病活动度评分、纤维化分级和性别分层分析18个药物靶点的调控。

主要发现

  • 在9项独立研究中差异表达基因的可重复性差,平均仅4%的差异基因在相同性别下被共同调控,2%在相同NAS疾病评分和纤维化分级下被共同调控。
  • 观察到性别特异性基因调控:女性中炎症反应、抗原呈递和处理相关基因表达诱导,男性中细胞外基质受体交互作用上调。
  • 除硬脂酰辅酶A去饱和酶外,大多数药物靶点在超过80%的患者中未受调控。

关键数值与推荐

  • 跨9项独立研究,平均4%的差异表达基因在相同性别下共同调控,2%在相同NAS评分和纤维化分级下共同调控。
  • 18个药物靶点中,除硬脂酰辅酶A去饱和酶外,大多数靶点在超过80%的患者中未受调控。

临床怎么用

  • 提示NASH药物研发需关注患者分层(如性别、疾病活动度)和靶点表达变异性,以提高临床试验成功率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: NAFLD is a major disease burden and a foremost cause of chronic liver disease. Presently, nearly 300 trials evaluate the therapeutic efficacy of > 20 drugs. Remarkably, the majority of drugs fail. To better comprehend drug failures, we investigated the reproducibility of fatty liver genomic data across 418 liver biopsies and evaluated the interpatient variability of 18 drug targets. APPROACH AND RESULTS: Apart from our own data, we retrieved NAFLD biopsy genomic data sets from public repositories and considered patient demographics. We divided the data into test and validation sets, assessed the reproducibility of differentially expressed genes and performed gene enrichment analysis. Patients were stratified by disease activity score, fibrosis grades and sex, and we investigated the regulation of 18 drug targets across 418 NAFLD biopsies of which 278 are NASH cases. We observed poor reproducibility of differentially expressed genes across 9 independent studies. On average, only 4% of differentially expressed genes are commonly regulated based on identical sex and 2% based on identical NAS disease score and fibrosis grade. Furthermore, we observed sex-specific gene regulations, and for females, we noticed induced expression of genes coding for inflammatory response, Ag presentation, and processing. Conversely, extracellular matrix receptor interactions are upregulated in males, and the data agree with clinical findings. Strikingly, and with the exception of stearoyl-CoA desaturase, most drug targets are not regulated in > 80% of patients. CONCLUSIONS: Lack of data reproducibility, high interpatient variability, and the absence of disease-dependent drug target regulations are likely causes of NASH drug failures in clinical trials.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Tang S, Borlak J. Genomics of human NAFLD: Lack of data reproducibility and high interpatient variability in drug target expression as major causes of drug failures. Hepatology. 2024. PMID: 38358517. doi:10.1097/HEP.0000000000000780

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。